Avacta Group Plc AVCT
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Avacta Group Plc shares you hold and we'll calculate your dividend payments:
Sign up for Avacta Group Plc and we'll email you the dividend information when they declare.
Add Avacta Group Plc to receive free notifications when they declare their dividends.
Your account is set up to receive Avacta Group Plc notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Avacta Group Plc dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0p | — |
| 2007 | 0.0p | 0% |
| 2008 | 0.0p | 0% |
| 2009 | 0.0p | 0% |
| 2010 | 0.0p | 0% |
| 2011 | 0.0p | 0% |
| 2012 | 0.0p | 0% |
| 2013 | 0.0p | 0% |
| 2014 | 0.0p | 0% |
| 2015 | 0.0p | 0% |
| 2016 | 0.0p | 0% |
| 2017 | 0.0p | 0% |
| 2018 | 0.0p | 0% |
| 2019 | 0.0p | 0% |
| 2020 | 0.0p | 0% |
| 2021 | 0.0p | 0% |
| 2022 | 0.0p | 0% |
| 2023 | 0.0p | 0% |
| 2024 | Sign Up Required | |
Avacta Group Plc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 23 December 2023
- 52 Week Low
- 0.0% on 23 December 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Avacta Group Plc
Avacta Group plc (Avacta) is a United Kingdom-based clinical stage oncology drug company. The Company is focused on developing cancer immunotherapies and diagnostics based on its Affimer and prelCISION platforms. It has two divisions: Therapeutics and Diagnostics. Avacta’s therapeutics division develops cancer immunotherapies combining its platforms: Affimer biotherapeutics and prelCISION tumor targeted chemotherapy. The Affimer platform is a class of biotherapeutic based on a naturally occurring human protein. Avacta's prelCISION targeted chemotherapy platform releases active chemotherapy in the tumor, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these anti-cancer treatments. Avacta’s diagnostics division utilizes its Affimer platform to develop diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty-bearing license deals.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United Kingdom
- Share Price
- £0.48 (yesterday's closing price)
- Shares in Issue
- 369 million
- Market Cap
- £175mn
- 0
- Market Indices
- none
